GlassScriptPhysician profile
Marla B Morgan
NPI 1003848821
$46,264.59
in general payments reported to CMS, 2019-2025
63 companies · $8,419 in 2025
The $8,419 reported for 2025 was more than what 88% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,409 · 2020: $4,682 · 2021: $6,711 · 2022: $10K · 2023: $2,098 · 2024: $12K · 2025: $8,419.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,165 · Consulting Fee: $7,500 · Travel and Lodging: $3,217 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,465 · Education: $94.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,164.58 |
| Consulting Fee | $7,500.00 |
| Travel and Lodging | $3,216.75 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,465.00 |
| Education | $94.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $30,005.93 | 2019-2025 | Ultomiris, Soliris |
| Abbvie INC. | $1,242.46 | 2021-2025 | |
| Biogen, INC. | $1,135.96 | 2019-2025 | Tysabri, Vumerity, Plegridy |
| Ucb, INC. | $992.58 | 2019-2025 | Briviact, Rystiggo, Zilbrysq |
| Neurocrine Biosciences, INC. | $846.22 | 2020-2025 | Ingrezza, Ongentys |
| Novartis Pharmaceuticals Corporation | $773.98 | 2019-2025 | |
| Neurelis, INC. | $656.84 | 2021-2025 | Valtoco |
| Allergan, INC. | $642.54 | 2019-2022 | |
| Pfizer INC. | $639.83 | 2019-2025 | |
| Amgen INC. | $561.44 | 2019-2025 | Aimovig, Uplizna |
| Sk Life Science, INC. | $517.35 | 2020-2025 | |
| Lilly USA, LLC | $505.54 | 2019-2025 | Amyvid, Kisunla, Emgality |
| Supernus Pharmaceuticals, INC. | $504.12 | 2019-2021 | |
| Eisai INC. | $496.73 | 2019-2025 | |
| Tg Therapeutics, INC. | $435.67 | 2024-2025 |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marla Morgan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.